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E-mail address: john.yarnold@icr.ac.uk (J. Yarnold)Background: A non-randomised phase II study suggested a therapeutic effect of hyperbaric oxygen (HBO)
therapy on arm lymphoedema following adjuvant radiotherapy for early breast cancer, justifying further
investigation in a randomised trial.
Methods: Fifty-eight patients with P15% increase in arm volume after supraclavicular ± axillary radio-
therapy (axillary surgery in 52/58 patients) were randomised in a 2:1 ratio to HBO (n = 38) or to best
standard care (n = 20). The HBO group breathed 100% oxygen at 2.4 atmospheres absolute for 100 min
on 30 occasions over 6 weeks. Primary endpoint was ipsilateral limb volume expressed as a percentage
of contralateral limb volume. Secondary endpoints included fractional removal rate of radioisotopic tra-
cer from the arm, extracellular water content, patient self-assessments and UK SF-36 Health Survey
Questionnaire.
Findings: Of 53/58 (91.4%) patients with baseline assessments, 46 had 12-month assessments (86.8%).
Median volume of ipsilateral limb (relative to contralateral) at baseline was 133.5% (IQR 126.0–
152.3%) in the control group, and 135.5% (IQR 126.5–146.0%) in the treatment group. Twelve months after
baseline the median (IQR) volume of the ipsilateral limb was 131.2% (IQR 122.7–151.5%) in the control
group and 133.5% (IQR 122.3–144.9%) in the treatment group. Results for the secondary endpoints were
similar between randomised groups.
Interpretation: No evidence has been found of a beneﬁcial effect of HBO in the treatment of arm lymphoe-
dema following primary surgery and adjuvant radiotherapy for early breast cancer.
 2010 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 97 (2010) 101–107Reports of hyperbaric oxygen (HBO) therapy in patients at risk
of mandibular necrosis following curative radiotherapy for cancer
suggest that the evolution of late onset radiation adverse effects
can be modiﬁed [1,2]. Treatment beneﬁt has also been reported
in patients with haemorrhagic cystitis and proctitis following pel-
vic radiation [3–20]. The pathological correlates of the response to
hyperbaric oxygen in irradiated tissues have been studied in ani-
mals, and include neovascularisation with organisation and reduc-
tion in ﬁbrous tissue [21]. Prospective randomised trials of HBO are
rare, and include a study reporting beneﬁts in radiation proctitisd Ltd. All rights reserved.
erapy Unit, The Royal Mars-
K.
.[22]. No serious adverse effects of HBO have been reported in
any of these studies.
In a previous study testing HBO in patients with radiation-in-
duced brachial plexopathy, we detected no evidence of effect
[23]. However, 2/6 cases with co-existing chronic arm lymphoe-
dema reported major and persistent improvements in arm volume
for at least 12 months after treatment with HBO. This observation
was not anticipated, and formed the basis for a non-randomised
phase II study in which 3/19 evaluable patients experienced
>20% reduction in arm volume at 12 months follow-up [24]. Six
of 13 evaluable patients also experienced a >25% improvement in
99Tc-nanocolloid clearance rate from the ipsilateral forearm at
12 months. Overall, there was a statistically signiﬁcant reduction
in ipsilateral arm volume at 12 months follow-up compared with
baseline (p = 0.005). It was this set of data that justiﬁed the current
randomised phase II trial.
102 Hyperbaric oxygen therapy for arm lymphoedemaPatients and methods
Eligibility and pre-treatment baseline assessments
Inclusion criteria included ipsilateral arm lymphoedema follow-
ing treatment for cancer causing P15% increase in arm volume,
freedom from cancer recurrence, physical and psychological ﬁtness
for HBO, availability for follow-up and written informed consent.
Pre-treatment assessment included advice on standard care for
lymphoedema, measurement of arm volume using a perometer,
patient self-assessments using a speciﬁc quality of life scale in
upper limb lymphoedema and the UK SF-36 Health Survey Ques-
tionnaire [25]. Patients randomised to the treatment group had
magnetic resonance imaging (MRI) of the supraclavicular fossa, ax-
illa and brachial plexus to exclude cancer recurrence; in the event
of recurrence, they were withdrawn from the study. There was a 3-
month run-in period between eligibility and baseline assessments
to ensure that all participants were receiving best standard care for
their lymphoedema according to the Lymphoedema Framework
Best Practice for the Management of Lymphoedema International
Consensus (2006) [26]. Baseline assessments included measure-
ment of lymph drainage in the forearm using lymphoscintigraphy
and of extracellular water content using a di-electric constant me-
ter in addition to perometer measurements and patient self-
assessments.
The trial was approved by Trent Multi-centre Research Ethics
Committee and Local Research Ethics Committees at all participat-
ing centres. It was registered as an International Standard Random-
ised Controlled Trial, No. ISRCTN00743308.Measurement of arm volume, quantitative lymphoscintigraphy and di-
electric constant meter measurements
Arm volumes were measured in an operator-independent man-
ner using a Perometer 400T limb volumeter (Pero-System, Wup-
pertal, Germany) [27,28]. The perometer consisted of a
horizontally mounted measuring frame inside which the depen-
dent arm was positioned. The frame was moved up and down
and volume in ml was automatically calculated from pairs of cir-
cumference measurements at 5 mm intervals from wrist to axilla,
obtained opto-electronically. The volume of the ipsilateral limb
was expressed as a percentage of the contralateral (control) limb
volume. Response was deﬁned in the protocol as P8% absolute
reduction in ipsilateral arm volume on the grounds that this was
considered a clinically worthwhile improvement unlikely to be
due to supportive measures or changes in lifestyle.
Lymphoscintigraphy was performed on as many volunteers as
possible at baseline and at 12 months follow-up. Patients were
acclimatised to their surroundings for at least 45 min before start-
ing. Patients lay supine with both arms resting on the gamma cam-
era detector ﬁtted with low energy, high resolution collimators
(Skylight, Philips Medical Systems, Cleveland, USA). A site on the
ventral surface of the ipsilateral forearm particularly affected by
swelling was selected for injection (typically one-third of the dis-
tance from the antecubital crease to the wrist). The site was
marked and the distance to the outstretched ﬁngertip and to the
olecranon process was measured in cm to enable relocation to
the same position for the repeat scan at 12 months. The corre-
sponding site on the contralateral arm was also marked. 99mTc-
Nanocoll (0.2 ml) in saline, containing approximately 20 MBq,
was injected subcutaneously in each forearm using a 1-ml syringe
and a 23-gauge needle. The site was not massaged. The arms were
positioned in supination on the camera face and a 60-s static acqui-
sition was performed. Acquisitions were repeated at 30, 60, 90, 120
and 180 min. Between acquisitions, the patient sat in a waiting
room. No exercise was performed. The number of counts recordedwithin a circular region of interest (area 80 cm2), encompassing the
depot, was obtained from the computer (Xeleris, GE). The removal
rate constant for the radiotracer, k (local lymph ﬂow per unit vol-
ume of distribution of tracer, units: % min1), was determined from
the regression slope of the plot of logn fraction of counts remaining
at the depot against time [29]. No formal deﬁnition of response
was agreed prior to the study.
Extracellular water content was measured on all volunteers at
baseline and 12 months later using di-electric constant measure-
ments [30,31]. The di-electric constant is a dimensionless physical
quantity and is directly proportional to the water content in the
measured tissue. Patients were acclimatised to their surroundings
in a prone position for at least 15 min before measurements were
taken. The patient lay on a bed, with both arms resting along the
body with palms facing up. Two sites were selected for measure-
ment; one-third of the distance from the antecubital crease to
the wrist (forearm) and one-half of the distance from the antecubi-
tal crease to the axilla (upper arm). The sites were marked, and the
distance between the wrist/axilla and the antecubital crease was
measured in cm to enable relocation to the same positions for re-
peat measurements at 12 months. Corresponding sites on the con-
tralateral arm were also marked. Measurements were taken using
a Delﬁn MoistureMeter-D (Delﬁn Technologies Ltd., www.delﬁn-
tech.com), an electronic control unit connected to a probe, which
recorded the di-electric constant of the skin and subcutaneous tis-
sue. The MoistureMeter-D uses a low power 300 MHz frequency,
and the measuring depth was adjusted by changing the size of
the probe (the M25 probe aimed to measure extracellular water
in the epidermis/dermis and the L50 probe aimed to measure to
5 mm depth). Three measurements were taken with each probe
at each site, and the mean of the three repeat readings at each site
was calculated. No formal deﬁnition of response was agreed prior
to the study.Quality of life
Patient self-assessments included a quality of life scale (as yet
unpublished) in upper limb lymphoedema developed and vali-
dated by a lymphoedema practitioner and the UK SF-36 Health
Survey Questionnaire [25]. The lymphoedema quality of life scale
consisted of 12 questions designed to assess restrictions to every-
day activities such as work, hobbies, bathing, sleep, shopping and
choice of clothing, together with pain and self awareness in a sim-
ilar format to the SF-36 questionnaire. The UK SF-36 Health Survey
Questionnaire is a generic, multi-purpose, short-form health sur-
vey with 36 questions, yielding an 8-scale proﬁle of functional
health and well-being scores as well as psychometrically based
physical and mental health summary measures and a preference-
based health utility index. Volunteers were asked to complete
the questionnaires before randomisation, at baseline assessments
3 months later (1 week prior to start of HBO for volunteers in the
treatment group), and 3, 6, 9 and 12 months after the baseline
assessments.Hyperbaric oxygen therapy or control
Research volunteers were randomised with a ratio of 2:1 (treat-
ment:control) after conﬁrmation of eligibility and consent proce-
dure by a telephone call to the randomisation service of The
Institute of Cancer Research Clinical Trials & Statistics Unit. At
the eligibility assessment 3 months prior to baseline assessments,
all volunteers were given advice on best standard care, and hosiery
was provided/adjusted if appropriate. Volunteers in the treatment
group were compressed to 2.4 atmospheres absolute (ATA)
(243 kPa) in a hyperbaric chamber at one of the ﬁve participating
hyperbaric medicine units. Patients breathed 100% oxygen at pres-
Table 1
Baseline patient characteristics.
Control; N = 20 (%) HBO; N = 38 (%)
Age: mean (SD) 62.1 (9.8) 63.2 (10.2)
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air breaks. Each participant received a total of 30 pressure expo-
sures, treating 5 days a week for 6 weeks. Volunteers in the control
group continued best standard care for lymphoedema.Primary surgery
None 1 (5.0) 2 (5.3)
Wide local excision 10 (50.0) 18 (47.4)
Mastectomy 9 (45.0) 18 (47.4)
Axillary surgery 18 (90.0) 34 (89.5)
Of those with axillary surgery:
Level I/II clearance 7/18 (38.9) 3/34 (8.8)
Level III clearance 5/18 (27.8) 12/34 (35.3)
Sampling 1/18 (5.5) 6/34 (17.6)
Level not known 5/18 (27.8) 13/34 (38.2)
Lymphatic RT
SCF only 5 (25.0) 20 (52.6)
Axilla only 4 (20.0) 6 (15.8)
SCF + axilla 11 (55.0) 12 (31.6)
Time from RT to
randomisation (yrs): mean (SD)
11.8 (9.7) 11.4 (8.6)
Time from randomisation
(eligibility assessment)
to start of HBO (days): mean (SD)
n/a 109.5 (24.2)Endpoints, sample size and analysis
The primary endpoint was deﬁned as an absolute change of
P8% in the relative volume of the ipsilateral arm vs. contralateral
arm at 12 months. Planned secondary endpoints included (i) lym-
phoscintigraphy, (ii) di-electric constant measurements and (iii)
patient self-assessments of arm swelling and physical functioning.
In our HBO pilot study of 19 evaluable patients with arm lym-
phoedema, the mean reduction in arm volume 12 months post-
therapy was 7.68% with standard deviation of 10.4 [24]. Using this
information, a sample size of 63 patients (42 treatment:21 control)
was deemed sufﬁcient to provide a clear test of efﬁcacy compared
with best standard management. Sixty-three patients provided
90% power to detect an 8% absolute difference (standardised differ-
ence of 0.8) between groups in the reduction of volume in the af-
fected arm (relative to the normal arm) at 12 months after start
of therapy compared with baseline (1-sided 5% signiﬁcance level).
Note that an 8% absolute reduction in pre-treatment ipsilateral arm
volume of 116% relative to contralateral arm volume represented a
50% reduction in arm swelling.
Nonparametric methods were used to summarise and analyse
the primary and secondary endpoints since distributions of the
data were skewed and no suitable transformation could be found.
Distributions were summarised using the median and interquartile
range (IQR). The Wilcoxon signed rank test was used to investigate
within-patient change from baseline to 12 months separately for
each treatment group. Change over time was then compared be-
tween control and HBO using the Mann–Whitney test. As well as
analysing the primary endpoint using the continuous data, perom-
eter measurements of arm volume were also categorised into re-
sponder vs. non-responder. Relative risk of response according to
treatment group was calculated with 95% conﬁdence intervals
(CI) and tested using the Fisher’s exact test.
Subscale scores for the SF-36 questionnaire were calculated
using the standard methods described in the scoring manual. The
upper limb lymphoedema-speciﬁc module of the quality of life
questionnaire was analysed by adding together the numerical re-
sponses to each of the individual questions to obtain a total score
which was transformed to a 0–100 scale – the same method used
for the subscales of the SF-36 questionnaire. Subscale scores were
summarised using the median and IQR for the control and HBO
groups at each time-point.
There was marked scatter of points for some patients’ lympho-
scintigraphy plots that made the ﬁtting of slopes difﬁcult. In some
cases activity appeared to increase after injection, a phenomenon
noted previously [32] but for which no explanation is available.
Two analyses of the lymphoscintigraphy data were undertaken:
(i) all acquisition points for each patient were included and slopes
ﬁtted to each plot accordingly; (ii) plots failing to show clearance
were excluded altogether and in other plots with outlying points
the latter were excluded before ﬁtting the regression slope. Both
sets of results are presented.Results
Patient demographics, compliance and treatment toxicities
Eligible patients interested to participate proved difﬁcult to
identify despite widespread publicity. Fifty-eight eligible research
volunteers with a minimum 15% increase in arm volume in the
years after supraclavicular ± axillary radiotherapy (axillary surgeryin 52/58 cases) were identiﬁed and randomised to continue treat-
ment according to best standard management for lymphoedema
(control group, n = 20) or to be treated with HBO (treatment group,
n = 38). 56/58 were breast cancer patients (55 females, 1 male),
and 2/58 had received radiotherapy for Hodgkin’s Lymphoma (1 fe-
male, 1 male). The baseline characteristics for the two randomised
groups were very similar, except for a higher rate of axillary sam-
pling rather than clearance in the HBO group (although numbers
very small), see Table 1.
Of the 58 patients randomised, baseline assessments were done
in 53 (91.4%): 17 control and 36 HBO. Of the 53 patients with base-
line assessments, 46 had 12-month assessments (86.8%): 16 con-
trol and 30 HBO. Reasons why patients did not have assessments
at baseline and 12 months are shown in Fig. 1.
5/38 patients reported toxicities due to HBO therapy but com-
pleted 30 sessions of treatment. 2/5 developed ear barotraumas
on ﬁrst dive and were offered bilateral myringotomies; 3/5 re-
ported some degree of myopia towards the end of treatment.Perometer measurements, lymphoscintigraphy and di-electric
constant meter measurements
Results of arm volume measurements at baseline and at
12 months follow-up are shown in Table 2. Forty-six of 58 volun-
teers were assessed at 12 months, 16 in the control group and 30
in the treatment group. The median volume of the ipsilateral limb
expressed as a percentage of contralateral limb volume at baseline
was 133.5% (IQR 126.0–152.3%) in the control group and 135.5%
(IQR 126.5–146.0%) in the treatment group. 12 months after base-
line the median (IQR) volume of the ipsilateral limb expressed as a
percentage of contralateral limb volume was 131.2% (IQR 122.7–
151.5%) in the control group and 133.5% (IQR 122.3–144.9%) in
the treatment group. The absolute median change from baseline
to 12 months was 0.3% (IQR 7.5% to 5.5%, p = 0.64) in the control
group and 2.9% (IQR 9.4% to 5.6%, p = 0.50) in the treatment
group. This small decrease in relative arm volume in both treat-
ment groups was not statistically signiﬁcant, and there were no
statistically signiﬁcant differences between randomised treatment
groups in terms of change over time.
In the trial protocol, ‘‘response” was deﬁned as P8% reduction
in ipsilateral arm volume relative to contralateral arm volume at
12 months. According to this deﬁnition, 30% (9/30) of patients in
n = 32 
Reasons why allocated treatment 
not received: 
1 pt missed 1 session due to ear 
barotrauma, cold & holiday; 
1 pt only had 7 sessions due to 
fever & vomiting, bone mets 
found; 
2 pts withdrew early (after 4 & 6 
sessions) as too much too cope 
with; 
2 pts diagnosed with mets post-
randomisation; 
n = 20 
Number 
randomised 
Allocated 
treatment 
Received 
allocated 
treatment 
Baseline data 
available 
12-month data 
available 
Number in 
analysis 
(baseline and 12-
month data 
available) 
Control:  
Best standard care 
n = 20 
Best standard care + hyperbaric 
oxygen therapy (30 sessions) 
n = 38 
n=58 
n = 17
Reasons: 
1 pt hospitalised at time of 
baseline assessment (pain in 
back & legs), withdrew consent; 
1 pt diagnosed with new primary 
tumour; 
1 pt unwilling to travel for 
assessments as in control 
group, withdrew consent; 
n = 36 
Reasons: 
1 pt diagnosed with mets post-
randomisation; 
1 pt found to have sternal mets 
on MRI scan pre-HBO therapy; 
n = 16 n = 30 
n = 16 
Reasons: 
1 pt diagnosed with bone mets; 
n = 30 
Reasons: 
3 pts diagnosed with mets; 
1 pt declined to attend for 
assessment as too far to travel; 
2 pts withdrew during treatment 
as too much to cope with; 
Fig. 1. Trial proﬁle for HOT trial.
104 Hyperbaric oxygen therapy for arm lymphoedemathe HBO group were classiﬁed as responders, compared with 18.8%
(3/16) in the control group, corresponding to a relative risk of being
a responder for HBO compared with control of 1.60 (95%CI 0.50–
5.09). This was not statistically signiﬁcant (p-value for Fisher’s ex-
act test, p = 0.50).
In both analyses (using complete and edited data), lymphatic
clearance rates were similar between the treatment groups at
baseline and at 12 months. The analysis of within-patient change
from baseline to 12 months showed that there was no clear
improvement for either treatment group (Table 3a and b).The analysis of change over time for the di-electric constant
measurements suggested a possible greater improvement (i.e.
reduction in ﬂuid volume) for HBO patients compared with control,
for the upper arm results (Table 4).Speciﬁc quality of life scale in upper limb lymphoedema together with
the UK SF-36 Health Survey Questionnaire
Table 5 and Fig. 2 show that patient ratings from the lymphoe-
dema-speciﬁc questionnaire were generally lower across the fol-
Table 2
Perometer measurements of arm volume at baseline and 12 months according to
treatment group.
Perometer measurements of arm
volume: median (interquartile range)
Control
N = 16 (%)
ml
HBO
N = 30 (%)
ml
Baseline
Ipsilateral arm volume 3350
(2659 to 4037)
3189
(2735 to 3971)
Contralateral arm volume 2550
(1921 to 2878)
2434
(1983 to 2821)
Ipsilateral/contralateral
arm volume (%)
133.5
(126.0 to 152.3)
135.5
(126.5 to 146.0)
12 months
Ipsilateral arm volume 3350
(2581 to 3897)
3061
(2673 to 4066)
Contralateral arm volume 2435
(2072 to 2841)
2326
(2046 to 2661)
Ipsilateral/contralateral
arm volume (%)
131.2
(122.7 to 151.5)
133.5
(122.3 to 144.9)
Change from baseline to 12 monthsa,b
Absolute change ipsilateral arm 3.5
(243.5 to 76.7)
p = 0.44
41.0
(166.0 to 59.5)
p = 0.14
Absolute change contralateral arm 1.0
(129.2 to 94.0)
p = 0.94
20.5
(82.5 to 65.5)
p = 0.55
Absolute change ipsilateral/
contralateral arm volume (%)
0.3
(7.5 to 5.5)
p = 0.64
2.9
(9.4 to 5.6)
p = 0.50
Results of Mann–Whitney tests comparing change in parameters over time
between control and HBO groups: ipsilateral arm p = 0.83; contralateral arm
p = 0.75; ipsilateral/contralateral arm p = 0.93.
a Change from baseline to 12 months expressed as (12 months – baseline); ve
indicates a decrease in arm volume (improvement) and +ve indicates an increase
(deterioration).
b Wilcoxon signed rank test for comparison of baseline vs. 12 months.
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fewer problems. Some patients also wrote comments in their ques-
tionnaire booklets indicating satisfaction with the treatment, and
observed improvements in arm movement. SF-36 subscale scores
for functioning, general health, etc. were very similar between
the treatment groups over time (data not shown).Discussion
This randomised trial failed to conﬁrm earlier reports of beneﬁt
of HBO in women with chronic arm lymphoedema following adju-Table 3
Lymphoscintigraphy data at baseline and 12 months according to treatment group.
Lymphatic clearance rate (% min1):
median (interquartile range)
All observed data included in anal
Control
N = 12 (%)
HB
N =
Baseline
Ipsilateral forearm 0.013
(0.035 to 0.006)
0
(
Contralateral forearm 0.056
(0.079 to 0.011)
0
(
12 months
Ipsilateral forearm 0.023
(0.073 to 0.005)
0
(
Contralateral forearm 0.059
(0.072 to 0.007)
0
(
Change from baseline to 12 monthsa
Absolute change ipsilateral forearm 0.009
(0.074 to 0.023)
0
(
Absolute change contralateral forearm 0.007
(0.032 to 0.075)
0.0
(
a Change from baseline to 12 months expressed as (12 months – baseline); ve indicvant radiotherapy to the lymphatic pathways [23,24]. One possible
explanation is that patients in our previous studies became better
at managing their lymphoedema through contact with other pa-
tients and health professionals during the course of the research.
In the current trial, there was a 3-month run-in period between
the eligibility assessments and treatment which ensured that all
participants received best standard care prior to HBO therapy.
One argument against this is that, in our previous study, lympho-
scintigraphy suggested improved clearance rates of extracellular
ﬂuid from the arm 12 months in 6/13 patients after HBO, a change
that would not be expected on the basis of better passive control of
arm volume [24].
There are several reasons why the present trial may have
missed a therapeutic effect. The small sample size increases the
risk of chance imbalances in prognostic factors between random-
ised groups and reduces the size of treatment effect that can be
reliably detected. Although the two groups were not perfectly bal-
anced with respect to treatment variables, differences in numbers
receiving axillary radiotherapy are not likely to be critical. In most
patients, the supraclavicular ﬁeld includes the level III nodes, and
standard tangential ﬁelds to the breast or chest wall include the
lower axilla (corresponding to level I). Perhaps the long average
interval (almost 12 years) between radiotherapy and HBO was just
too long to enable remodelling of mature ﬁbrotic tissue, although
one of the most dramatic complete responses in our ﬁrst study
was seen in a woman with gross lymphoedema of 20 years dura-
tion [23]. The long average interval in the present trial reﬂected
the scarcity of patients currently treated in the UK with axillary
radiotherapy, a practice that may now be returning in the context
of positive axillary sentinel node biopsy [33]. On an individual pa-
tient basis, it is not possible to assess the relative contributions of
axillary surgery and lymphatic radiotherapy to arm lymphoedema.
If axillary surgery was the dominant causative factor for lymphoe-
dema, the trial may have missed a therapeutic effect of HBO on the
radiotherapy-induced element. This would mean that the patient
population could not offer proof of principle that HBO had an effect
against radiation-induced arm lymphoedema. Although the patho-
genesis of lymphoedema caused by surgery and radiotherapy is not
well understood, there are likely to be similarities that render
uncertainty over the relative contributions of the two causative
agents largely irrelevant.
The only secondary endpoint raising the possibility of therapeu-
tic effect was a comparison of response rate in the randomised
groups. Thirty percent (9/30) of patients in the HBO group were
classiﬁed as responders, compared with 18.8% (3/16) in the controlysis Unreliable data excluded from analysis
O
28 (%)
Control
N = 12 (%)
HBO
N = 28 (%)
.040
0.056 to 0.014)
0.052
(0.125 to 0.031)
0.058
(0.096 to 0.048)
.064
0.079 to 0.027)
0.066
(0.125 to 0.054)
0.081
(0.140 to 0.057)
.050
0.069 to 0.020)
0.104
(0.139 to 0.056)
0.074
(0.113 to 0.051)
.051
0.087 to 0.017)
0.066
(0.077 to 0.061)
0.087
(0.113 to 0.053)
.015
0.035 to 0.007)
0.062
(0.103 to 0.085)
0.013
(0.024 to 0.018)
06
0.023 to 0.040)
0.007
(0.021 to 0.201)
0.003
(0.045 to 0.046)
ates an improvement in clearance rate and +ve a deterioration.
Table 4
Dielectric constant measurements of extracellular water content at baseline and 12 months according to treatment group.
Di-electric measurements of arm ﬂuid volume change
from baseline to 12 monthsa: median (interquartile range)
Probe used Control
N = 13b (%)
HBO
N = 30 (%)
Ipsilateral upper arm Skin 0.7 (2.5 to 4) 2.0 (4.2 to 1.7)
Contralateral upper arm Skin 0 (1.2 to 1.3) 0 (1.4 to 0.7)
Ipsilateral forearm Skin 0.7 (3 to 2.7) 1.8 (3.2 to 4.3)
Contralateral forearm Skin 1 (1 to 2.2) 1.3 (0.7 to 2.4)
Ipsilateral upper arm Subcutaneous 0.3 (0.7 to 2.5) 1.3 (3.5 to 1.2)
Contralateral upper arm Subcutaneous 0 (0.3 to 1) 0.3 (1.4 to 0)
Ipsilateral forearm Subcutaneous 0.3 (4.2 to 3.2) 0.3 (3.1 to 4.7)
Contralateral forearm Subcutaneous 0.3 (1.0 to 0.8) 1.0 (0.7 to 2.1)
a Change from baseline to 12 months expressed as (12 months – baseline); ve indicates decrease in arm ﬂuid volume (improvement) and +ve an increase (deterioration).
b Three missing.
Table 5
Patient self-assessments of effects of lymphoedema from baseline to 12 months
according to treatment group.
Total standardised score from
lymphoedema questionnairea
(range 0–100); median (IQR)
Control HBO
Baseline 47.9 50.0
N = 17 control and 35 HBO (18.7–64.6) (27.1–64.6)
3 months 58.3 33.3
N = 17 control and 33 HBO (20.8–66.7) (20.8–59.4)
6 months 47.9 32.3
N = 16 control and 32 HBO (18.7–64.1) (17.7–53.6)
9 months 33.3 43.7
N = 16 control and 32 HBO (15.1–64.6) (19.3–58.3)
12 months 45.8 37.5
N = 16 control and 31 HBO (13.0–62.5) (20.8–52.1)
a Higher scores reﬂect worse effects of lymphoedema on activities, etc.
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Fig. 2. Patient self-assessments of effects of lymphoedema according to time-point
and treatment group.
106 Hyperbaric oxygen therapy for arm lymphoedemagroup, a difference that was not statistically signiﬁcant. Neither of
the functional measures of lymphatic clearance, including rate of
clearance of extracellular water measured by lymphoscintigraphy
and size of extracellular compartment measured using di-electric
constant, suggested that a therapeutic effect of HBO was missed
by the volume measurements. The reproducibility of the former
measurements was not high, placing limits on the sensitivity of
this technique to small differences in clearance rate. The patient
self-assessments of functional outcome and quality of life were
also consistent with the external measures of HBO effect in report-
ing no differences between randomised groups. In conclusion, thisrandomised trial has not conﬁrmed earlier reports of a therapeutic
effect of HBO on arm lymphoedema following primary surgery and
radiotherapy for early breast cancer.
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